Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed.

In this CME podcast activity, Dr. David Rubin and Dr. Peter Higgins will discuss investigational anti-integrin therapies for UC.

For the transcript of this podcast, click here

To obtain CME credit, click here